CANGENE Corp. has started 2013 with a bang.
At the beginning of the year, it announced the U.S. Food and Drug Administration has approved a drug called Varizig for use in high-risk patient groups such as immunocompromised children, newborns and pregnant women who have been exposed to chickenpox.
Last week, the Winnipeg biotech company acquired a hemophilia compound that is in late-stage clinical trial from a company that is under bankruptcy protection in the U.S.
Then this week, it issued a press release saying it passed a major hurdle in a lengthy project to get the FDA to license its botulism antitoxin BAT.
Cangene developed BAT under a $427-million contract with the U.S. Department of Health and Human Services.
Click here for the article.